Ex­clu­sive: Ohana, Flag­ship's big bet on fer­til­i­ty treat­ments, shuts down and lays off staff af­ter VC pulls the plug

A lit­tle over a year af­ter emerg­ing from stealth, Flag­ship’s grand at­tempt to re­make fer­til­i­ty is shut­ting down.

Ohana Bio­sciences CEO Am­ber Salz­man con­firmed in an email to End­points News that the board — over­whelm­ing­ly drawn from Flag­ship’s ranks — de­cid­ed on Tues­day to wind down the com­pa­ny af­ter they failed to raise enough cash to keep it go­ing. They are cut­ting staff to “min­i­mal op­er­a­tions,” she said, while work­ing to find new po­si­tions for laid off em­ploy­ees.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER